These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 37686617)
1. Differences in the Tumor Molecular and Microenvironmental Landscape between Early (Non-Metastatic) and De Novo Metastatic Primary Luminal Breast Tumors. Lambrechts Y; Hatse S; Richard F; Boeckx B; Floris G; Desmedt C; Smeets A; Neven P; Lambrechts D; Wildiers H Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686617 [No Abstract] [Full Text] [Related]
2. The clinicomolecular landscape of de novo versus relapsed stage IV metastatic breast cancer. Seltzer S; Corrigan M; O'Reilly S Exp Mol Pathol; 2020 Jun; 114():104404. PubMed ID: 32067942 [TBL] [Abstract][Full Text] [Related]
3. Genomic Characterization of Garrido-Castro AC; Spurr LF; Hughes ME; Li YY; Cherniack AD; Kumari P; Lloyd MR; Bychkovsky B; Barroso-Sousa R; Di Lascio S; Jain E; Files J; Mohammed-Abreu A; Krevalin M; MacKichan C; Barry WT; Guo H; Xia D; Cerami E; Rollins BJ; MacConaill LE; Lindeman NI; Krop IE; Johnson BE; Wagle N; Winer EP; Dillon DA; Lin NU Clin Cancer Res; 2021 Feb; 27(4):1105-1118. PubMed ID: 33293374 [TBL] [Abstract][Full Text] [Related]
4. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry. Müller V; Hein A; Hartkopf AD; Fasching PA; Kolberg HC; Hadji P; Tesch H; Häberle L; Ettl J; Lüftner D; Wallwiener M; Beckmann MW; Schneeweiss A; Belleville E; Uhrig S; Wimberger P; Hielscher C; Meyer J; Wurmthaler LA; Kurbacher CM; Wuerstlein R; Untch M; Janni W; Taran FA; Lux MP; Wallwiener D; Brucker SY; Fehm TN; Michel LL Eur J Cancer; 2022 Sep; 172():13-21. PubMed ID: 35728342 [TBL] [Abstract][Full Text] [Related]
5. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010. Malmgren JA; Mayer M; Atwood MK; Kaplan HG Breast Cancer Res Treat; 2018 Jan; 167(2):579-590. PubMed ID: 29039120 [TBL] [Abstract][Full Text] [Related]
6. Epidemiology of De Novo Metastatic Breast Cancer. Daily K; Douglas E; Romitti PA; Thomas A Clin Breast Cancer; 2021 Aug; 21(4):302-308. PubMed ID: 33750642 [TBL] [Abstract][Full Text] [Related]
7. Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand. Lao C; Kuper-Hommel M; Elwood M; Campbell I; Edwards M; Lawrenson R Breast Cancer; 2021 Mar; 28(2):387-397. PubMed ID: 33044617 [TBL] [Abstract][Full Text] [Related]
8. Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients. McKenzie HS; Maishman T; Simmonds P; Durcan L; ; Eccles D; Copson E Br J Cancer; 2020 May; 122(11):1618-1629. PubMed ID: 32231292 [TBL] [Abstract][Full Text] [Related]
9. Does definitive local therapy have a role in select HER2+ de novo metastatic breast cancer patients treated with dual anti-HER2 blockade? Rosier L; Wang Y; Lee JH; Daily K Breast Cancer Res Treat; 2022 Jan; 191(2):375-383. PubMed ID: 34787760 [TBL] [Abstract][Full Text] [Related]
10. De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis. Gaillard T; Carton M; Mailliez A; Desmoulins I; Mouret-Reynier MA; Petit T; Leheurteur M; Dieras V; Ferrero JM; Uwer L; Guiu S; Gonçalves A; Levy C; Debled M; Dalenc F; Patsouris A; Bachelot T; Eymard JC; Chevrot M; Conversano A; Robain M; Hequet D Eur J Cancer; 2021 Oct; 158():181-188. PubMed ID: 34689042 [TBL] [Abstract][Full Text] [Related]
12. Aggressive local therapy for Liu B; Liu H; Liu M Oncol Rep; 2023 Sep; 50(3):. PubMed ID: 37449542 [TBL] [Abstract][Full Text] [Related]
13. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies. Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437 [TBL] [Abstract][Full Text] [Related]
15. The Role of Primary Surgery in Demirors B; Goktepe B; Medeck H; Ozbas S; Soran A Eur J Breast Health; 2023 Apr; 19(2):110-114. PubMed ID: 37025581 [TBL] [Abstract][Full Text] [Related]
16. Use and results of systemic treatments for de novo and recurrent metastatic breast cancer: a population-based cohort study. Lao C; Kuper-Hommel M; Campbell I; Elwood M; Lawrenson R N Z Med J; 2021 Nov; 134(1545):47-59. PubMed ID: 34788271 [TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic factors associated with de novo metastatic breast cancer. Shen T; Siegal GP; Wei S Pathol Res Pract; 2016 Dec; 212(12):1167-1173. PubMed ID: 27692496 [TBL] [Abstract][Full Text] [Related]
18. Clinical information and management status of de novo stage IV breast cancer patients: a Chinese multicenter investigation (CSBrS-002). Zheng A; Guo BL; Zhang JG; Jin F; Chin Med J (Engl); 2021 Jun; 134(13):1569-1575. PubMed ID: 34101635 [TBL] [Abstract][Full Text] [Related]